This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Analysis of Expression of Nitric Oxide Syntheses and Their Functional Role in Human Urothelium

This study has been terminated.
Zealand University Hospital
Information provided by:
Copenhagen University Hospital at Herlev Identifier:
First received: November 11, 2005
Last updated: October 6, 2006
Last verified: October 2006

Painful bladder syndrome (PBS)/interstitial cystitis (IC) may be due to the actions of nitric oxide (NO) in the bladder tissue. NO is a gaseous substance with a very short half-life, synthesized by a group of NO-synthase-enzymes in many tissues.

The goal of this study is to illuminate bladder tissue production of NO in individuals with PBS and healthy individuals, by quantification of NO and NO-enzyme expression by different molecular biological methods.

Condition Intervention
Interstitial Cystitis Bladder Diseases Urinary Incontinence Procedure: Tissue examination for protein- and mRNA-expression of NO

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Cross-Sectional
Time Perspective: Retrospective/Prospective
Official Title: A Quantitative Analysis of Protein- and mRNA-Expression of Nitric Oxide Syntheses and Their Functional Role in Human Urothelium

Resource links provided by NLM:

Further study details as provided by Copenhagen University Hospital at Herlev:

Estimated Enrollment: 60
Study Start Date: January 2006
Estimated Study Completion Date: January 2008

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • PBS/IC according to International Continence Society (ICS)
  • Cystoscopy with bladder distension and deep biopsies within last 5 years
  • Cystometry within last 5 years
  • Normal urine culture within last month

Inclusion Criteria (for control group):

  • Benign non-invasive bladder disease
  • No PBS/IC
  • Normal urine culture
  • No functional bladder disease of known nature (ex. infravesical obstruction)

Exclusion Criteria:

  • Age under 18 years
  • Inability to understand instructions
  • Pregnancy and lactation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00253006

Copenhagen University Hospital at Herlev
Herlev, Denmark, DK- 2730
Sponsors and Collaborators
Copenhagen University Hospital at Herlev
Zealand University Hospital
Study Director: Pierre Bouchelouche, MD Roskilde County University Hospital at Koege, Dept. of Clinical Biochemistry
  More Information

Publications: Identifier: NCT00253006     History of Changes
Other Study ID Numbers: UA_H_Ka-05104-m
Study First Received: November 11, 2005
Last Updated: October 6, 2006

Keywords provided by Copenhagen University Hospital at Herlev:
painful bladder syndrome

Additional relevant MeSH terms:
Urinary Incontinence
Cystitis, Interstitial
Urinary Bladder Diseases
Urination Disorders
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Behavioral Symptoms
Elimination Disorders
Mental Disorders
Nitric Oxide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Free Radical Scavengers
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Endothelium-Dependent Relaxing Factors
Vasodilator Agents
Protective Agents processed this record on September 21, 2017